Skip to content Skip to footer
Subscribe Now
NEWS

Tolerance Bio and Tanabe Pharma Partner for MT-2990 in Deal With Up to $560M in Milestones

Shots: Tolerance Bio has entered into an exclusive license agreement with Tanabe Pharma for MT-2990, an anti-IL-33 monoclonal antibody, across all indications Tanabe Pharma has granted Tolerance Bio worldwide development & manufacturing rights, and ex-Japan exclusive commercialization rights for MT-2990 (TLB-33), while Tanabe will retain commercialization rights in Japan As per the deal, Tanabe will…
September 30, 2026

Read more

NEWS

Tolerance Bio Licenses Efineptakin Alfa from NeoImmuneTech to Advance Thymic Function and Immune Resilience Programs

Shots: Tolerance Bio entered into an exclusive license agreement with NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), for certain thymus-related indications in the Americas and Europe. The company also plans to initiate P-II studies evaluating the therapy for enhancement of thymic function Under the agreement, Tolerance Bio will advance efineptakin alfa alongside…
August 20, 2026

Read more